Q&A summary for the Q1 of the fiscal year ending March 2027. Reflecting improvements in raw material procurement conditions and ongoing procurement challenges and elevated prices for some items, the full-year outlook has moved from undecided to disclosed. Adjusted EBITDA is expected to be about 13% higher YoY at 2.21 billion yen, while depreciation due to capex is expected to cause a substantial decline in operating income and ordinary income YoY. The biopharma segment is expected to grow strongly, while the pharmaceutical segment is in a preparatory phase with slower growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6568","jir_company_name":"Kobe Tamba Kagaku Kabushiki Kaisha","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/6568-20260831-01.pdf","jir_short_summary":"Q&A summary for the Q1 of the fiscal year ending March 2027. Reflecting improvements in raw material procurement conditions and ongoing procurement challenges and elevated prices for some items, the full-year outlook has moved from undecided to disclosed. Adjusted EBITDA is expected to be about 13% higher YoY at 2.21 billion yen, while depreciation due to capex is expected to cause a substantial decline in operating income and ordinary income YoY. The biopharma segment is expected to grow strongly, while the pharmaceutical segment is in a preparatory phase with slower growth.","jir_summary":"### Overview of performance\nThe full-year outlook for this period has shifted from undecided to disclosed. The raw material procurement environment is showing an improving trend, but continued supply disruptions and elevated prices for certain materials persist. Adjusted EBITDA is expected to be about 13% higher YoY at 2.21 billion yen, while depreciation from capital expenditure increases is expected to reduce operating income and ordinary income YoY. The impact of raw material risk response costs is expected to be limited, depending on progress from the second quarter onward. The biopharma segment is expected to grow steadily, and the pharmaceutical segment is in the preparatory stage with slower growth anticipated for future mass-production projects.\n\n### Key outlook and risks\nProcurement difficulties for raw materials and packaging materials remain in part, but the group will prioritize productivity and profitability. The pace of substitutions and the lag in passing higher raw material costs to selling prices could affect the full-year earnings forecast, leading to a conservative outlook. Looking ahead, imports from regions outside the Middle East are expected to increase, which should ease logistics congestion, but vigilance remains for high price levels.","jir_financial_highlights":"Full-year outlook: From undecided to disclosed ( undecided \u2192 disclosed)\nAdjusted EBITDA: 2.21 billion yen (YoY about 13% increase)\nOperating income: Unknown (YoY decline)\nOrdinary income: Unknown (YoY decline)\nCosts to address raw material procurement risks: \u25b30.1 billion yen (Progress expected from Q2 onward)","jir_category":"","jir_hashtags":"#KobeTambaKagaku, #Earnings, #FullYearOutlook, #AdjustedEBITDA, #RawMaterialProcurementRisk","jir_key_figures":"Adjusted EBITDA: 2.21 billion yen (YoY about 13% increase)\nCosts to address raw material procurement risks: \u25b30.1 billion yen\nFull-year outlook: From undecided to disclosed (currently undecided)","jir_meta_title":"\u3010Kobe Tamba Kagaku\u3011Q1 FY2027 Earnings Q&A Summary\uff5cImproved Raw Material Procurement Environment and Full-Year Outlook","jir_meta_description":"Q1 FY2027 earnings Q&A summary for Kobe Tamba Kagaku. Improved raw material procurement environment, adjusted EBITDA up 13% YoY, but operating and ordinary income expected to decline due to higher capital expenditure. Discusses segment trends and key risk factors going forward.","jir_og_title":"Kobe Tamba Kagaku\uff5cQ1 Earnings Q&A Summary","jir_og_description":"Discusses improved raw material procurement environment and disclosure of full-year outlook, with growth prospects for the pharmaceutical and biopharma sectors and associated risk factors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59165,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-108672","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n